<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02934217</url>
  </required_header>
  <id_info>
    <org_study_id>2013-830</org_study_id>
    <nct_id>NCT02934217</nct_id>
  </id_info>
  <brief_title>Does Cyclosporine ImpRove Clinical oUtcome in ST Elevation Myocardial Infarction Patients at 3 Years of Follow-up. CIRCUS II Study</brief_title>
  <acronym>CIRCUS II</acronym>
  <official_title>Does Cyclosporine ImpRove Clinical oUtcome in ST Elevation Myocardial Infarction Patients at 3 Years of Follow-up. CIRCUS II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infarct size is a major determinant of vital prognosis after AMI. We recently reported that&#xD;
      cyclosporine A, when administered immediately prior to PCI reperfusion, can significantly&#xD;
      reduce infarct size in STEMI patients. The CIRCUS study aimed at determining the impact of&#xD;
      cyclosporine on the combined incidence of (death, hospitalization for heart failure, LV&#xD;
      remodelling) at one year after AMI. However, many patients may display increased adverse LV&#xD;
      remodelling beyond year 1 and develop heart failure thereafter. The present CIRCUS II trial&#xD;
      aims at examining the 3-year clinical outcome of all patients recruited in the CIRCUS study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2014</start_date>
  <completion_date type="Actual">June 28, 2017</completion_date>
  <primary_completion_date type="Actual">June 28, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined incidence of [total mortality; hospitalization for heart failure; LV remodeling (increase of LV end-diastolic volume &gt; 15%)]</measure>
    <time_frame>at 12 months post-AMI.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first event [total mortality, hospitalization for heart failure]</measure>
    <time_frame>until 3 years post-AMI</time_frame>
    <description>Functional outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total mortality</measure>
    <time_frame>at 12 months post-AMI.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total mortality</measure>
    <time_frame>at 3 years post-AMI.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>at 3 years post-AMI.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>at 12 months post-AMI.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart failure</measure>
    <time_frame>at 12 months post-AMI.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart failure</measure>
    <time_frame>at 3 years post-AMI.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>at 12 months post-AMI.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>at 3 years post-AMI.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unstable angina</measure>
    <time_frame>at 12 months post-AMI.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unstable angina</measure>
    <time_frame>at 3 years post-AMI.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>at 12 months post-AMI.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>at 3 years post-AMI.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infarct size</measure>
    <time_frame>at 12 months post-AMI.</time_frame>
    <description>Measured by cardiac MRI, only for patients included in participating centers where cardiac MRI is part of the usual post-infarct care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infarct size</measure>
    <time_frame>at 3 years post-AMI.</time_frame>
    <description>Measured by cardiac MRI, only for patients included in participating centers where cardiac MRI is part of the usual post-infarct care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>at 3 years post-AMI.</time_frame>
    <description>Assessed by the EQ-5D-3L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>at 3 years post-AMI.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ejection fraction</measure>
    <time_frame>at 12 months post-AMI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left-ventricular End-Diastolic Volume (LVEDV)</measure>
    <time_frame>at 12 months post-AMI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left-ventricular End-Systolic Volume (LVESV)</measure>
    <time_frame>at 12 months post-AMI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infarct size: peak Troponin (T or I)</measure>
    <time_frame>at 4 hours (+/- 30 minutes) after study treatment administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microvascular obstruction</measure>
    <time_frame>at 48 hours post-AMI</time_frame>
    <description>assessed by Magnetic resonance imaging</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">868</enrollment>
  <condition>ST Elevation Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Cyclosporin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>one single intravenous bolus injection of 2.5 mg/Kg Echocardiography</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>one single intravenous bolus injection of Placebo Echocardiography</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Injection of Cyclosporin</intervention_name>
    <description>one single intravenous bolus injection of 2.5 mg/Kg</description>
    <arm_group_label>Cyclosporin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One single intravenous bolus injection of Placebo</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Echocardiography</intervention_name>
    <description>3 years after AMI</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Cyclosporin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All (male and female) patients, aged over 18, without any legal protection measure,&#xD;
&#xD;
          -  Having a health coverage,&#xD;
&#xD;
          -  Presenting within 12 hours of the onset of chest pain,&#xD;
&#xD;
          -  Who have ST segment elevation ≥0.2 mV in two contiguous leads,&#xD;
&#xD;
          -  For whom the clinical decision was made to treat with percutaneous coronary&#xD;
             intervention (PCI).&#xD;
&#xD;
        And (further inclusion criteria to be confirmed by the admission coronary-angiography):&#xD;
&#xD;
          -  The culprit coronary artery has to be the LAD&#xD;
&#xD;
          -  The LAD artery has to be occluded (TIMI flow grade 0-1) at the time of admission&#xD;
             coronary angiography.&#xD;
&#xD;
          -  Preliminary oral informed consent followed by signed informed consent as soon as&#xD;
             possible.&#xD;
&#xD;
        Patients undergoing either primary PCI or rescue PCI are eligible for the study. Patients&#xD;
        with previous AMI, PCI or coronary artery bypass surgery (CABG) are eligible for the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with loss of consciousness or confused&#xD;
&#xD;
          -  Patients with cardiogenic shock&#xD;
&#xD;
          -  Patients with the left circumflex or the right coronary artery (RCA) as the culprit&#xD;
             artery, or with evidence of coronary collaterals to the risk region&#xD;
&#xD;
          -  Patients with an opened (TIMI &gt; 1) LAD coronary artery at admission on initial&#xD;
             (admission) coronary angiography&#xD;
&#xD;
          -  Patients with 1. known hypersensitivity to cyclosporine 2. known hypersensitivity to&#xD;
             egg, peanut or Soya-bean proteins 3. known renal insufficiency (either known creatinin&#xD;
             clearance &lt; 30 ml/min/1.73m² or current medical care for severe renal insufficiency)&#xD;
             4. known liver insufficiency 5. uncontrolled (treated or untreated) hypertension (&gt;&#xD;
             180/110 mmHg)&#xD;
&#xD;
          -  Patients treated with any compound containing Hypericum perforatum (St.-John's-worth)&#xD;
             or Stiripentol or Aliskiren or Bosentan or Rosuvastatine&#xD;
&#xD;
          -  Female patients currently pregnant or women of childbearing age who were not using&#xD;
             contraception (oral diagnosis).&#xD;
&#xD;
          -  Patients with any disorder associated with immunological dysfunction more recently&#xD;
             than 6 months prior to presentation 1. cancer, lymphoma 2. known positive serology for&#xD;
             HIV, or hepatitis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel OVIZE, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Louis Pradel</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>October 13, 2016</study_first_submitted>
  <study_first_submitted_qc>October 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2016</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

